imiquimod has been researched along with luteolin-7-glucoside in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Albanesi, C; Avigliano, L; Cavani, A; Madonna, S; Mauriello, A; Melino, G; Palombo, R; Savini, I; Terrinoni, A | 1 |
2 other study(ies) available for imiquimod and luteolin-7-glucoside
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model.
Topics: Acanthosis Nigricans; Aminoquinolines; Animals; Cell Differentiation; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cellular Senescence; Disease Models, Animal; Glucosides; Humans; Imiquimod; Immunohistochemistry; Inflammation; Interleukin-22; Interleukins; Keratinocytes; Lipids; Luteolin; Mice, Inbred C57BL; Oxidation-Reduction; Phenotype; Protein Transport; Psoriasis; Signal Transduction; STAT3 Transcription Factor | 2016 |